Business

MannKind Corporation announced a strategic financing agreement with Blackstone that will provide the company with a $75 million loan initially, with a total potential of up to $500 million. MannKind said that the agreement was made in… Read more . . .

Alveolus Bio, which is developing inhaled therapies for the treatment of respiratory diseases, announced that Indian API manufacturer and CDMO Shilpa Medicare Limited has led a strategic financing round that will fund Phase 2 development… Read more . . .

GSK has announced that it will pay $500 million to Hengrui Pharma up front for the rights to Hengrui’s HRS-9821, an inhaled dry powder PDE3/4 inhibitor for the treatment of COPD, plus options to license… Read more . . .

Avalyn Pharma announced that it has closed a $100 million Series D financing, with proceeds intended to support continued development of its inhaled drugs for the treatment of pulmonary fibrosis, including AP01 pirfenidone, AP02 nintedanib,… Read more . . .

Merck has announced that it will acquire Ohtuvarye inhaled ensifentrine maker Verona Pharma for a total of approximately $10 billion. Ohtuvarye, which is delivered via jet nebulizer, was approved by the FDA in June 2024… Read more . . .

Oragenics announced that it has raised approximately $16.5 million in a Series H funding round, with proceeds going toward repayment of a $3 million bridge loan and continued development of the company’s OPN-002 neurosteroid nasal… Read more . . .

Lupin announced that it has signed an agreement with Sino Universal Pharmaceuticals for commercialization of Lupin’s tiotropium dry powder inhaler in China for the treatment of COPD. Per the agreement, Sino Universal will obtain marketing… Read more . . .

Transpire Bio announced that it has acquired an exclusive license to develop Suzhou Intragrand Pharma’s ITG-1052, a PDE4 inhibitor, as an inhaled therapeutic for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases. The… Read more . . .